Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Chronic Heart Failure

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 195 articles: HTML format

Single Articles

November 2021
1. ROALFE AK, Lay-Flurrie SL, Ordonez-Mena JM, Goyder CR, et al
   Long term trends in natriuretic peptide testing for heart failure in UK primary care: a cohort study.
   Eur Heart J. 2021 Nov 30. pii: 6437771. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. CRUMP C, Sundquist J, McLaughlin MA, Dolan SM, et al
   Pre-term delivery and long-term risk of heart failure in women: a national cohort and co-sibling study.
   Eur Heart J. 2021 Nov 24. pii: 6438093. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. CREA F
   Mechanisms of heart failure with preserved ejection fraction, risk stratification of heart failure with reduced ejection fraction, and new light on resistance to diuretics in acute decompensated heart failure.
   Eur Heart J. 2021;42:4405-4409.
   PubMed    
   
   
   
4. PITT B, Ferreira JP, Zannad F
   Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI.
   Eur Heart J. 2021 Nov 12. pii: 6425576. doi: 10.1093.
   PubMed    
   
   
   
5. ISHIURA J, Nakamori S, Ishida M, Dohi K, et al
   'Targeting the cardiac myocyte and fibrosis' in heart failure.
   Eur Heart J. 2021 Nov 10. pii: 6425003. doi: 10.1093.
   PubMed    
   
   
   
6. LUND LH, Hage C, Savarese G
   Implementation science and potential for screening in heart failure.
   Eur Heart J. 2021 Nov 9. pii: 6424186. doi: 10.1093.
   PubMed    
   
   
   
7. EGIDY ASSENZA G, Dimopoulos K, Budts W, Donti A, et al
   Management of acute cardiovascular complications in pregnancy.
   Eur Heart J. 2021;42:4224-4240.
   PubMed     Abstract available
   
   
   October 2021
8. BUTLER J, Anker SD, Filippatos G, Usman MS, et al
   Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
   Eur Heart J. 2021 Oct 30. pii: 6414464. doi: 10.1093.
   PubMed    
   
   
   
9. SEFEROVIC PM, Piepoli M, Polovina M, Milinkovic I, et al
   ESC/HFA Quality of Care Centres: the ultimate frontier in unifying heart failure management.
   Eur Heart J. 2021 Oct 28. pii: 6413707. doi: 10.1093.
   PubMed    
   
   
   
10. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the
    Eur Heart J. 2021 Oct 14. pii: 6397185. doi: 10.1093.
    PubMed    
    
    
    
11. BRAUNWALD E
    Heart failure with preserved ejection fraction: a stepchild no more!
    Eur Heart J. 2021;42:3900-3901.
    PubMed    
    
    
    
12. SATTAR N, Anker SD, Butler J, Verma S, et al
    Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights.
    Eur Heart J. 2021 Oct 7. pii: 6383062. doi: 10.1093.
    PubMed    
    
    
    
13. LINDE C
    Pace and ablate better than drugs in patients with heart failure and atrial fibrillation: lessons from the APAF-CRT mortality trial.
    Eur Heart J. 2021 Oct 6. pii: 6382271. doi: 10.1093.
    PubMed    
    
    
    September 2021
14. CREA F
    The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
    Eur Heart J. 2021;42:3581-3585.
    PubMed    
    
    
    
15. ZHAO Y, Ling S, Li J, Zhong G, et al
    3' untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein.
    Eur Heart J. 2021;42:3786-3799.
    PubMed     Abstract available
    
    
    
16. CHEN QQ, Ma G, Liu JF, Cai YY, et al
    Neuraminidase 1 is a driver of experimental cardiac hypertrophy.
    Eur Heart J. 2021;42:3770-3782.
    PubMed     Abstract available
    
    
    
17. WUSSLER D, Mueller C
    Biomarker-driven prognostic model for risk prediction in heart failure: ready for Prime time?
    Eur Heart J. 2021 Sep 17. pii: 6371853. doi: 10.1093.
    PubMed    
    
    
    
18. SINHA A, Rahman H, Webb A, Shah AM, et al
    Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction.
    Eur Heart J. 2021 Sep 16. pii: 6371296. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. MARTENS P, Tang WHW, Mullens W
    Renal sodium avidity, the prevailing renal target in heart failure.
    Eur Heart J. 2021 Sep 16. pii: 6371295. doi: 10.1093.
    PubMed    
    
    
    
20. COX ZL, Rao VS, Ivey-Miranda JB, Moreno-Villagomez J, et al
    Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure.
    Eur Heart J. 2021 Sep 16. pii: 6371304. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. 
    Erratum to: CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
    Eur Heart J. 2021 Sep 14. pii: 6370281. doi: 10.1093.
    PubMed    
    
    
    
22. JANKOWSKA EA, Ponikowski P
    Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure?
    Eur Heart J. 2021 Sep 14. pii: 6370026. doi: 10.1093.
    PubMed    
    
    
    
23. CREA F
    The ESC Guidelines on cardiac pacing and resynchronization, and the many facets of atrial fibrillation.
    Eur Heart J. 2021;42:3411-3414.
    PubMed    
    
    
    
24. GLIKSON M, Nielsen JC, Kronborg MB, Michowitz Y, et al
    2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
    Eur Heart J. 2021;42:3427-3520.
    PubMed    
    
    
    
25. BAYES-GENIS A, Diez J
    Transition to heart failure in hypertension: going to the heart of the matter.
    Eur Heart J. 2021 Sep 13. pii: 6369562. doi: 10.1093.
    PubMed    
    
    
    
26. LEWIS EF
    A fourth pillar for all in the treatment of heart failure.
    Eur Heart J. 2021 Sep 13. pii: 6369563. doi: 10.1093.
    PubMed    
    
    
    
27. KAHN M, Grayson AD, Chaggar PS, Ng Kam Chuen MJ, et al
    Primary care heart failure service identifies a missed cohort of heart failure patients with reduced ejection fraction.
    Eur Heart J. 2021 Sep 11. pii: 6368904. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. BROWN JM, Zhou W, Weber B, Divakaran S, et al
    Low coronary flow relative to myocardial mass predicts heart failure in symptomatic hypertensive patients with no obstructive coronary artery disease.
    Eur Heart J. 2021 Sep 7. pii: 6365821. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2021
29. YILMAZ MB
    Does early angiography pave the way for improved outcomes in patients with acute heart failure?
    Eur Heart J. 2021 Aug 31. pii: 6360027. doi: 10.1093.
    PubMed    
    
    
    
30. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    Eur Heart J. 2021 Aug 27. pii: 6358045. doi: 10.1093.
    PubMed    
    
    
    
31. LIGHT PE
    Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure.
    Eur Heart J. 2021 Aug 27. pii: 6358226. doi: 10.1093.
    PubMed    
    
    
    
32. CURTAIN JP, Docherty KF, Jhund PS, Petrie MC, et al
    Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
    Eur Heart J. 2021 Aug 27. pii: 6358075. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. POCOCK SJ, Ferreira JP, Gregson J, Anker SD, et al
    Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Aug 23. pii: 6356321. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. CREA F
    The complex relationship among heart failure, cancer, and lipid lowering, and an update on cardiomyopathies.
    Eur Heart J. 2021;42:3029-3032.
    PubMed    
    
    
    
35. BERGER M, Solelhac G, Roche F, Heinzer R, et al
    Insomnia, a new modifiable risk factor for heart failure?
    Eur Heart J. 2021 Aug 21. pii: 6355986. doi: 10.1093.
    PubMed    
    
    
    
36. WITHAAR C, Lam CSP, Schiattarella GG, de Boer RA, et al
    Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.
    Eur Heart J. 2021 Aug 20. pii: 6355308. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. KEMPF T
    Iron supplementation in acute heart failure: energize your life.
    Eur Heart J. 2021;42:3021-3022.
    PubMed    
    
    
    
38. VOLPE M, Gallo G
    Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
    Eur Heart J. 2021 Aug 15. pii: 6352588. doi: 10.1093.
    PubMed    
    
    
    
39. MAHMOOD A, Ray M, Dobalian A, Ward KD, et al
    Insomnia symptoms and incident heart failure: a population-based cohort study.
    Eur Heart J. 2021 Aug 15. pii: 6352589. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. WAGNER JUG, Dimmeler S
    The endothelial niche in heart failure: from development to regeneration.
    Eur Heart J. 2021 Aug 15. pii: 6352586. doi: 10.1093.
    PubMed    
    
    
    
41. JACKSON AM, Jhund PS, Anand IS, Dungen HD, et al
    Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
    Eur Heart J. 2021 Aug 15. pii: 6352587. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. DIVAKARAN S, Nohria A
    Decoding the link between heart failure and incident cancer.
    Eur Heart J. 2021 Aug 14. pii: 6352225. doi: 10.1093.
    PubMed    
    
    
    
43. WANG N, Sun Y, Zhang H, Wang B, et al
    Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.
    Eur Heart J. 2021 Aug 10. pii: 6347324. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. NICHOLLS M
    New perspectives on heart failure.
    Eur Heart J. 2021 Aug 6. pii: 6343116. doi: 10.1093.
    PubMed    
    
    
    July 2021
45. KOSYAKOVSKY LB, Austin PC, Ross HJ, Wang X, et al
    Early invasive coronary angiography and acute ischaemic heart failure outcomes.
    Eur Heart J. 2021 Jul 30. pii: 6331345. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. TUAL-CHALOT S, Stellos K
    Drug repurposing to prevent pressure overload-induced cardiac hypertrophy and heart failure.
    Eur Heart J. 2021 Jul 13. pii: 6319852. doi: 10.1093.
    PubMed    
    
    
    
47. DA DALT L, Castiglioni L, Baragetti A, Audano M, et al
    PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction.
    Eur Heart J. 2021 Jul 12. pii: 6319627. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. 
    European Heart Journal Team Heart Failure.
    Eur Heart J. 2021 Jul 5. pii: 6314555. doi: 10.1093.
    PubMed    
    
    
    
49. ONO M, Garg S, Onuma Y, Serruys PW, et al
    Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data?
    Eur Heart J. 2021 Jul 1. pii: 6311994. doi: 10.1093.
    PubMed    
    
    
    June 2021
50. LAM CSP, Ferreira JP, Pfarr E, Sim D, et al
    Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Jun 29. pii: 6310468. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. REN QW, Yu SY, Teng TK, Li X, et al
    Statin associated lower cancer risk and related mortality in patients with heart failure.
    Eur Heart J. 2021 Jun 22. pii: 6307232. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. CREA F
    The Universal Definition of Heart Failure, risk prediction in cardiogenic shock, artificial intelligence in cardiac allograft rejection, and the genetics of dilated cardiomyopathy.
    Eur Heart J. 2021;42:2317-2320.
    PubMed    
    
    
    
53. NICHOLLS M
    Recognition for heart failure breakthrough.
    Eur Heart J. 2021 Jun 11. pii: 6296965. doi: 10.1093.
    PubMed    
    
    
    
54. JANKOWSKA EA, Kirwan BA, Kosiborod M, Butler J, et al
    The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
    Eur Heart J. 2021 Jun 3. pii: 6291468. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. ZANNAD F, Cotter G, Alonso Garcia A, George S, et al
    What can heart failure trialists learn from oncology trialists?
    Eur Heart J. 2021 Jun 2. pii: 6291019. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2021
56. VOLZ S, Redfors B, Angeras O, Ioanes D, et al
    Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Eur Heart J. 2021 May 23. pii: 6282431. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. MARSTON NA, Han L, Olivotto I, Day SM, et al
    Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy.
    Eur Heart J. 2021;42:1988-1996.
    PubMed     Abstract available
    
    
    
58. PORCHER R, Desguerre I, Amthor H, Chabrol B, et al
    Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data.
    Eur Heart J. 2021;42:1976-1984.
    PubMed     Abstract available
    
    
    
59. NICHOLLS M
    Telemedicine for chronic heart failure patients.
    Eur Heart J. 2021 May 13. pii: 6274945. doi: 10.1093.
    PubMed    
    
    
    
60. HAMDANI N, Costantino S, Mugge A, Lebeche D, et al
    Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.
    Eur Heart J. 2021 May 5. pii: 6264879. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2021
61. 
    Corrigendum to: Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.
    Eur Heart J. 2021 Apr 24. pii: 6248970. doi: 10.1093.
    PubMed    
    
    
    
62. CREA F
    Emerging causes and risk factors of heart failure: amyloidosis, myocarditis, immune checkpoint inhibitors, air pollution, and visceral adipose tissue.
    Eur Heart J. 2021;42:1533-1537.
    PubMed    
    
    
    
63. RAJAGOPALAN S, Brook RD, Al-Kindi S
    Air pollution and flooding in the lungs: modern insights into ancient problems.
    Eur Heart J. 2021;42:1592-1594.
    PubMed    
    
    
    
64. WITHAAR C, Meems LMG, de Boer RA
    Fighting HFpEF in women: taking aim at belly fat.
    Eur Heart J. 2021;42:1606-1608.
    PubMed    
    
    
    
65. FULLENKAMP DE, Puckelwartz MJ, McNally EM
    Genome-wide association for heart failure: from discovery to clinical use.
    Eur Heart J. 2021 Apr 14. pii: 6225796. doi: 10.1093.
    PubMed    
    
    
    
66. 
    Erratum to: Conducting Clinical Trials in Heart Failure During (and After) the COVID-19 Pandemic: An Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur Heart J. 2021 Apr 7. pii: 6214477. doi: 10.1093.
    PubMed    
    
    
    
67. BAUERSACHS J
    The struggle towards a Universal Definition of Heart Failure-how to proceed?
    Eur Heart J. 2021 Apr 1. pii: 6206998. doi: 10.1093.
    PubMed    
    
    
    March 2021
68. CREA F
    Challenges in heart failure: quality of life, chronic kidney disease, and secondary mitral regurgitation.
    Eur Heart J. 2021;42:1185-1189.
    PubMed    
    
    
    
69. SPERTUS JA
    Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care.
    Eur Heart J. 2021;42:1213-1215.
    PubMed    
    
    
    
70. FUKUOKA R, Kawamura A, Kohsaka S
    Prediction of sudden arrhythmic death in patients with heart failure: towards validation in a worldwide broader range of patients.
    Eur Heart J. 2021 Mar 18. pii: 6177055. doi: 10.1093.
    PubMed    
    
    
    
71. COATS AJS, Anker SD, Baumbach A, Alfieri O, et al
    The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and
    Eur Heart J. 2021 Mar 18. pii: 6174642. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. YOUNIS A, Goldenberg I
    Extending the MADIT-ICD benefit score to heterogenous heart failure populations.
    Eur Heart J. 2021 Mar 18. pii: 6177051. doi: 10.1093.
    PubMed    
    
    
    
73. VOLPE M, Patrono C
    The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending.
    Eur Heart J. 2021 Mar 10. pii: 6168016. doi: 10.1093.
    PubMed    
    
    
    
74. GARNIER S, Harakalova M, Weiss S, Mokry M, et al
    Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.
    Eur Heart J. 2021 Mar 3. pii: 6157424. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. VAN DIEPEN S, Armstrong PW
    Learning whether to subtract beta-blockers: it's about time.
    Eur Heart J. 2021;42:915-918.
    PubMed     Abstract available
    
    
    February 2021
76. VOLPE M, Patrono C
    Iron heart.
    Eur Heart J. 2021;42:809-810.
    PubMed    
    
    
    
77. DIDERIKSEN JR, Christiansen MK, Johansen JB, Nielsen JC, et al
    Long-term outcomes in young patients with atrioventricular block of unknown aetiology.
    Eur Heart J. 2021 Feb 18. pii: 6143533. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. VILLRINGER A, Laufs U
    Heart failure, cognition, and brain damage.
    Eur Heart J. 2021 Feb 16. pii: 6139887. doi: 10.1093.
    PubMed    
    
    
    
79. HALLIDAY BP, Senior R, Pennell DJ
    Assessing left ventricular systolic function: from ejection fraction to strain analysis.
    Eur Heart J. 2021;42:789-797.
    PubMed     Abstract available
    
    
    
80. CREA F
    New guidelines on adult congenital heart disease, the fantastic four in the treatment of heart failure, and also what happened in the last year in heart failure and valvular heart disease.
    Eur Heart J. 2021;42:551-554.
    PubMed    
    
    
    
81. 
    Corrigendum to: The Year in Cardiovascular Medicine: Heart Failure and Cardiomyopathies. The Year in Cardiovascular Medicine 2020.
    Eur Heart J. 2021 Feb 11. pii: 6132731. doi: 10.1093.
    PubMed    
    
    
    
82. PETRIE MC, Lee MM, Lang NN
    EMPEROR-REDUCED reigns while EMPERIAL whimpers.
    Eur Heart J. 2021;42:711-714.
    PubMed    
    
    
    
83. WANG M, Zhou T, Song Y, Li X, et al
    Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank.
    Eur Heart J. 2021 Feb 2. pii: 6126215. doi: 10.1093/eurheartj/ehaa1031.
    PubMed     Abstract available
    
    
    January 2021
84. LOCH A, Koh PS, Manokaran P
    Giant hepatic cyst masquerading as right heart failure.
    Eur Heart J. 2021 Jan 30. pii: 6124029. doi: 10.1093.
    PubMed    
    
    
    
85. FREY A, Homola GA, Henneges C, Muhlbauer L, et al
    Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failure-the COGNITION.MATTERS-HF cohort study.
    Eur Heart J. 2021 Jan 26. pii: 6120261. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. 
    Corrigendum to: Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure?
    Eur Heart J. 2021;42:319.
    PubMed    
    
    
    
87. MASSIMO V, Carlo P
    Truly galactic?
    Eur Heart J. 2021;42:296-297.
    PubMed    
    
    
    
88. EVANS MA, Sano S, Walsh K
    Clonal haematopoiesis and cardiovascular disease: how low can you go?
    Eur Heart J. 2021;42:266-268.
    PubMed    
    
    
    
89. SMISETH OA, Aalen JM, Skulstad H
    Heart failure and systolic function: time to leave diagnostics based on ejection fraction?
    Eur Heart J. 2021 Jan 17. pii: 6075085. doi: 10.1093.
    PubMed    
    
    
    
90. BAUERSACHS J
    Heart failure drug treatment: the fantastic four.
    Eur Heart J. 2021 Jan 14. pii: 6099035. doi: 10.1093/eurheartj/ehaa1012.
    PubMed    
    
    
    
91. CSENGERI D, Sprunker NA, Di Castelnuovo A, Niiranen T, et al
    Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes.
    Eur Heart J. 2021 Jan 13. pii: 6090248. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. HOLT A, Blanche P, Zareini B, Rajan D, et al
    Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.
    Eur Heart J. 2021 Jan 11. pii: 6082772. doi: 10.1093/eurheartj/ehaa1058.
    PubMed     Abstract available
    
    
    
93. PACKER M, Anker SD, Butler J, Filippatos G, et al
    Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Jan 11. pii: 6081935. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. BUTLER J, Anker SD, Filippatos G, Khan MS, et al
    Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Jan 9. pii: 6072066. doi: 10.1093/eurheartj/ehaa1007.
    PubMed     Abstract available
    
    
    
95. CREA F
    Machine learning-guided phenotyping of dilated cardiomyopathy and treatment of heart failure by antisense oligonucleotides: the future has begun.
    Eur Heart J. 2021;42:139-142.
    PubMed    
    
    
    
96. DEVAUX Y, Badimon L
    CDR132L: another brick in the wall towards the use of miRNAs to treat cardiovascular disease.
    Eur Heart J. 2021;42:202-204.
    PubMed    
    
    
    
97. AGARWAL R, Kolkhof P, Bakris G, Bauersachs J, et al
    Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
    Eur Heart J. 2021;42:152-161.
    PubMed     Abstract available
    
    
    
98. FURHOLZ M, Gisler F, Hunziker L, Huber AT, et al
    Posture dependent dynamic external outflow graft compression in HeartMate 3TM left ventricular assist device.
    Eur Heart J. 2021;42:205.
    PubMed    
    
    
    
99. BUENO H, Moura B, Lancellotti P, Bauersachs J, et al
    The year in cardiovascular medicine 2020: heart failure and cardiomyopathies.
    Eur Heart J. 2021 Jan 3. pii: 6060054. doi: 10.1093/eurheartj/ehaa1061.
    PubMed    
    
    
    December 2020
100. 
     Corrigendum to: How to Diagnose Heart Failure with Preserved Ejection Fraction - The HFA-PEFF-SCORE An updated Consensus Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
     Eur Heart J. 2020 Dec 29. pii: 6055039. doi: 10.1093/eurheartj/ehaa1016.
     PubMed    
     
     
     
101. ABRAHAM WT, Lindenfeld J, Ponikowski P, Agostoni P, et al
     Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
     Eur Heart J. 2020 Dec 22. pii: 6044442. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. BAKER AH, Giacca M
     Antagonism of miRNA in heart failure: first evidence in human.
     Eur Heart J. 2020 Dec 18. pii: 6041762. doi: 10.1093.
     PubMed    
     
     
     
103. ROY R, Koch WJ
     Adding another GRK to the fire of heart failure.
     Eur Heart J. 2020 Dec 7. pii: 6025474. doi: 10.1093.
     PubMed    
     
     
     November 2020
104. PITT B, Byrd JB
     Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.
     Eur Heart J. 2020 Nov 30. pii: 6012925. doi: 10.1093.
     PubMed    
     
     
     
105. ASSMUS B, Cremer S, Kirschbaum K, Culmann D, et al
     Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
     Eur Heart J. 2020 Nov 26. pii: 6006386. doi: 10.1093.
     PubMed     Abstract available
     
     
     
106. SORIMACHI H, Obokata M, Takahashi N, Reddy YNV, et al
     Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction.
     Eur Heart J. 2020 Nov 23. pii: 5998959. doi: 10.1093.
     PubMed     Abstract available
     
     
     
107. BOHM M, Mahfoud F
     J-curve revisited.
     Eur Heart J. 2020;41:4283.
     PubMed    
     
     
     
108. LIEW CH, McEvoy JW
     The diastolic blood pressure J-curve remains an observational research phenomenon that has not yet been proven as causal and should not be used to make invasive treatment decisions.
     Eur Heart J. 2020;41:4284-4285.
     PubMed    
     
     
     
109. FEDCHENKO M, Mandalenakis Z, Giang KW, Rosengren A, et al
     Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study.
     Eur Heart J. 2020 Nov 21. pii: 5997447. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. CLELAND JGF, Ferreira JP, Mariottoni B, Pellicori P, et al
     The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
     Eur Heart J. 2020 Nov 20. pii: 5993916. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. ALFONSO F
     Heart Failure 2019.
     Eur Heart J. 2020 Nov 17. pii: 5986679. doi: 10.1093.
     PubMed    
     
     
     
112. TAUBEL J, Hauke W, Rump S, Viereck J, et al
     Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.
     Eur Heart J. 2020 Nov 11. pii: 5974817. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2020
113. 
     Corrigendum to: Treatment of heart failure with reduced ejection fraction: the dawn of sodium-glucose cotransporter-2 inhibitors.
     Eur Heart J. 2020 Oct 22. pii: 5935857. doi: 10.1093.
     PubMed    
     
     
     
114. BATKAI S, Genschel C, Viereck J, Rump S, et al
     CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
     Eur Heart J. 2020 Oct 22. pii: 5934677. doi: 10.1093.
     PubMed     Abstract available
     
     
     
115. CREA F
     The multiple causes and treatments of heart failure: focus on genetic and molecular mechanisms and non-pharmacological interventions.
     Eur Heart J. 2020;41:3769-3773.
     PubMed    
     
     
     
116. BONNET M, Champagnac A, Lantelme P, Harbaoui B, et al
     Endomyocardial biopsy findings in Kawasaki-like disease associated with SARS-CoV-2.
     Eur Heart J. 2020;41:3863-3864.
     PubMed    
     
     
     
117. PETTIT SJ
     HeartMate 3: real-world performance matches pivotal trial.
     Eur Heart J. 2020;41:3810-3812.
     PubMed    
     
     
     
118. LIUZZO G, Patrono C
     EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial.
     Eur Heart J. 2020 Oct 7. pii: 5918827. doi: 10.1093.
     PubMed    
     
     
     September 2020
119. CREA F
     Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
     Eur Heart J. 2020;41:3379-3383.
     PubMed    
     
     
     
120. 
     Corrigendum to: Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure? [Eur Heart J 2020;41: 2411].
     Eur Heart J. 2020 Sep 15. pii: 5906090. doi: 10.1093.
     PubMed    
     
     
     
121. BUTLER J, Zannad F, Filippatos G, Anker SD, et al
     Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.
     Eur Heart J. 2020 Sep 15. pii: 5906091. doi: 10.1093.
     PubMed    
     
     
     
122. SAVARESE G, Cosentino F
     The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns.
     Eur Heart J. 2020 Sep 9. pii: 5903162. doi: 10.1093.
     PubMed    
     
     
     August 2020
123. SERENELLI M, Bohm M, Inzucchi SE, Kober L, et al
     Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
     Eur Heart J. 2020 Aug 21. pii: 5895186. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2020
124. HARARI R, Bangalore S
     Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!
     Eur Heart J. 2020 Jul 30. pii: 5879119. doi: 10.1093.
     PubMed    
     
     
     
125. FIGLIOZZI S, Rizzo S, De Gaspari M, Tarantini G, et al
     End-stage heart failure secondary to low-dose hydroxychloroquine treatment.
     Eur Heart J. 2020 Jul 29. pii: 5877566. doi: 10.1093.
     PubMed    
     
     
     
126. 
     Corrigendum to: How to slice the pie: heart failure subgroups and their clinical meaning.
     Eur Heart J. 2020 Jul 25. pii: 5876171. doi: 10.1093.
     PubMed    
     
     
     
127. ESCANED J, Lerman LO
     Coronary microcirculation and hypertensive heart failure.
     Eur Heart J. 2020;41:2376-2378.
     PubMed    
     
     
     
128. LUSCHER TF
     How to slice the pie: heart failure subgroups and their clinical meaning.
     Eur Heart J. 2020;41:2339-2343.
     PubMed    
     
     
     
129. SCHMIDT IM, Verma A, Waikar SS
     Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease.
     Eur Heart J. 2020;41:3097-3098.
     PubMed    
     
     
     June 2020
130. KARASON K, Jamaly S
     Heart failure development in obesity: mechanistic pathways.
     Eur Heart J. 2020 Jun 18. pii: 5859181. doi: 10.1093.
     PubMed    
     
     
     
131. ZHOU Y, Liu F, Nie J
     Does hypoperfusion outperformed blood pressure as a better predictor in the risk stratification of acute heart failure?
     Eur Heart J. 2020 Jun 18. pii: 5859700. doi: 10.1093.
     PubMed    
     
     
     
132. BOCCHINO PP, Angelini F, Frea S
     Intravenous vasodilators in acute heart failure patients with low basic blood pressure: may the benefit come from targeting perfusion rather than pressure?
     Eur Heart J. 2020 Jun 18. pii: 5859697. doi: 10.1093.
     PubMed    
     
     
     
133. KIM J, Kang D, Park H, Kang M, et al
     Long-term beta-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.
     Eur Heart J. 2020 Jun 15. pii: 5857797. doi: 10.1093.
     PubMed     Abstract available
     
     
     
134. ANKER SD, Butler J, Khan MS, Abraham WT, et al
     Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
     Eur Heart J. 2020 Jun 4. pii: 5851435. doi: 10.1093.
     PubMed     Abstract available
     
     
     
135. CULEBRAS E, Hernandez F
     ACE2 is on the X chromosome: could this explain COVID-19 gender differences?
     Eur Heart J. 2020;41:3095.
     PubMed    
     
     
     May 2020
136. PACKER M
     Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure.
     Eur Heart J. 2020 May 27. pii: 5847945. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. SAMA IE, Ravera A, Santema BT, van Goor H, et al
     Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
     Eur Heart J. 2020;41:1810-1817.
     PubMed     Abstract available
     
     
     
138. OUDIT GY, Pfeffer MA
     Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19.
     Eur Heart J. 2020;41:1818-1820.
     PubMed    
     
     
     
139. INCIARDI RM, Adamo M, Lupi L, Cani DS, et al
     Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy.
     Eur Heart J. 2020;41:1821-1829.
     PubMed     Abstract available
     
     
     
140. THUM T
     SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-pandemic wave of heart failure?
     Eur Heart J. 2020 May 8. pii: 5834515. doi: 10.1093.
     PubMed    
     
     
     
141. OZKAN J
     Trying times for heart failure trials during the COVID-19 pandemic.
     Eur Heart J. 2020;41:1715.
     PubMed    
     
     
     
142. LUSCHER TF
     Cardio-oncology and the future of heart failure.
     Eur Heart J. 2020;41:1709-1712.
     PubMed    
     
     
     
143. PITT B
     Mark Nicholls speaks to Professor Bertram Pitt and his role as a pioneer in cardiology over the management of heart failure.
     Eur Heart J. 2020;41:1615-1617.
     PubMed    
     
     
     
144. MILLER VM
     Universality of sex differences in cardiovascular outcomes: where do we go from here?
     Eur Heart J. 2020;41:1697-1699.
     PubMed    
     
     
     April 2020
145. PACKER M
     Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care.
     Eur Heart J. 2020 Apr 29. pii: 5827051. doi: 10.1093.
     PubMed    
     
     
     
146. BOHM M, Bewarder Y, Kindermann I
     Ejection fraction in heart failure revisited- where does the evidence start?
     Eur Heart J. 2020 Apr 29. pii: 5827050. doi: 10.1093.
     PubMed    
     
     
     
147. BARTKO PE, Hulsmann M, Hung J, Pavo N, et al
     Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction.
     Eur Heart J. 2020 Apr 29. pii: 5827049. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. BAYES-GENIS A, Liu PP, Lanfear DE, de Boer RA, et al
     Omics phenotyping in heart failure: the next frontier.
     Eur Heart J. 2020 Apr 26. pii: 5825477. doi: 10.1093.
     PubMed     Abstract available
     
     
     
149. TAHARA A, Tahara N, Maeda-Ogata S, Bekki M, et al
     Brown adipose tissue activation in severe heart failure.
     Eur Heart J. 2020 Apr 24. pii: 5824912. doi: 10.1093.
     PubMed    
     
     
     
150. LUSCHER TF
     Sex and gender and cardiovascular medicine: impact in diabetes, acute coronary syndromes, and heart failure.
     Eur Heart J. 2020;41:1311-1314.
     PubMed    
     
     
     March 2020
151. LAM CSP, Voors AA, Piotr P, McMurray JJV, et al
     Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction.
     Eur Heart J. 2020 Mar 30. pii: 5813810. doi: 10.1093.
     PubMed    
     
     
     
152. VADUGANATHAN M, Jhund PS, Claggett BL, Packer M, et al
     A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.
     Eur Heart J. 2020 Mar 28. pii: 5813082. doi: 10.1093.
     PubMed     Abstract available
     
     
     
153. ZHOU W, Brown JM, Bajaj NS, Chandra A, et al
     Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure.
     Eur Heart J. 2020 Mar 28. pii: 5813079. doi: 10.1093.
     PubMed     Abstract available
     
     
     
154. DOCHERTY KF, Jhund PS, Inzucchi SE, Kober L, et al
     Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
     Eur Heart J. 2020 Mar 28. pii: 5813081. doi: 10.1093.
     PubMed     Abstract available
     
     
     
155. VAN DER LINGEN ACJ, Allaart CP
     The role of implantable cardioverter-defibrillators in New York Heart Class I heart failure patients: do not abandon the asymptomatic just yet.
     Eur Heart J. 2020 Mar 25. pii: 5811615. doi: 10.1093.
     PubMed    
     
     
     
156. GOLDENBERG I, Huang DT, Nielsen JC
     The role of implantable cardioverter-defibrillators in asymptomatic patients with left ventricular dysfunction.
     Eur Heart J. 2020 Mar 25. pii: 5811613. doi: 10.1093.
     PubMed    
     
     
     
157. LUSCHER TF
     Ejection fraction to classify heart failure: are we using the right thing?
     Eur Heart J. 2020;41:1219-1222.
     PubMed    
     
     
     
158. MOTIEJUNAITE J, Akiyama E, Cohen-Solal A, Maggioni AP, et al
     The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions.
     Eur Heart J. 2020 Mar 3. pii: 5775572. doi: 10.1093.
     PubMed     Abstract available
     
     
     
159. SLIWA K
     Heart failure can affect everyone: the ESC Geoffrey Rose lecture.
     Eur Heart J. 2020 Mar 2. pii: 5771280. doi: 10.1093.
     PubMed     Abstract available
     
     
     
160. BOHM M, Ferreira JP, Mahfoud F, Duarte K, et al
     Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial.
     Eur Heart J. 2020 Mar 2. pii: 5771273. doi: 10.1093.
     PubMed     Abstract available
     
     
     
161. MESSERLI FH, Bangalore S, Messerli AW, Raber L, et al
     The muddy waters of the J-curve and coronary revascularization.
     Eur Heart J. 2020 Mar 2. pii: 5771269. doi: 10.1093.
     PubMed    
     
     
     February 2020
162. JAMALYAN S
     Surgical obesity treatment and the risk of heart failure: the possible mechanisms of interaction and diagnostic accuracy.
     Eur Heart J. 2020 Feb 24. pii: 5753975. doi: 10.1093.
     PubMed    
     
     
     
163. AZAR RR, Abdelmassih T
     Innovation in Heart Failure: from Pills to Devices.
     Eur Heart J. 2020;41:906-907.
     PubMed    
     
     
     
164. VAN WOERDEN G, van Veldhuisen SL, Rienstra M
     Incident heart failure risk after bariatric surgery: the role of epicardial fat.
     Eur Heart J. 2020 Feb 20. pii: 5741377. doi: 10.1093.
     PubMed    
     
     
     January 2020
165. ZHOU Y, Wen J, Nie J
     How much can acute heart failure patients with low basic blood pressure (systolic blood pressure 90-100 mmHg) benefit from the use of vasodilators?
     Eur Heart J. 2020 Jan 10. pii: 5700445. doi: 10.1093.
     PubMed    
     
     
     
166. CLELAND JGF, Lyon AR, McDonagh T, McMurray JJV, et al
     The year in cardiology: heart failure.
     Eur Heart J. 2020 Jan 6. pii: 5694316. doi: 10.1093.
     PubMed    
     
     
     
167. MCMURRAY JJV, Solomon SD, Docherty KF, Jhund PS, et al
     The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context.
     Eur Heart J. 2020 Jan 3. pii: 5695523. doi: 10.1093.
     PubMed    
     
     
     December 2019
168. COHEN-SOLAL A
     Iron deficiency in heart failure: why so frequent and which mechanisms?
     Eur Heart J. 2019 Dec 20. pii: 5682455. doi: 10.1093.
     PubMed    
     
     
     
169. MALMBORG M, Schmiegelow MDS, Norgaard CH, Munch A, et al
     Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?
     Eur Heart J. 2019 Dec 20. pii: 5682397. doi: 10.1093.
     PubMed     Abstract available
     
     
     
170. SCHOU M, Kober L
     Sudden death in heart failure: do we understand what we observe?
     Eur Heart J. 2019 Dec 10. pii: 5671749. doi: 10.1093.
     PubMed    
     
     
     
171. LAM CSP, Arnott C, Beale AL, Chandramouli C, et al
     Sex differences in heart failure.
     Eur Heart J. 2019 Dec 4. pii: 5652224. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2019
172. BARRA S, Providencia R, Narayanan K, Boveda S, et al
     Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review.
     Eur Heart J. 2019 Nov 21. pii: 5637310. doi: 10.1093.
     PubMed     Abstract available
     
     
     
173. LUSCHER TF
     Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes.
     Eur Heart J. 2019;40:3579-3582.
     PubMed    
     
     
     
174. GOLDENBERG I, Huang DT, Nielsen JC
     The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome.
     Eur Heart J. 2019 Nov 12. pii: 5622905. doi: 10.1093.
     PubMed     Abstract available
     
     
     
175. OMLAND T
     Targeting the endothelin system: a step towards a precision medicine approach in heart failure with preserved ejection fraction?
     Eur Heart J. 2019 Nov 4. pii: 5612120. doi: 10.1093.
     PubMed    
     
     
     October 2019
176. NG ACT, Bax JJ
     Hyperdynamic left ventricular function and the prognostic implications for heart failure with preserved ejection fraction.
     Eur Heart J. 2019 Oct 25. pii: 5607286. doi: 10.1093.
     PubMed    
     
     
     
177. HONARBAKHSH S, Prabhu S, Hunter RJ
     With our powers combined: Does the pooled analysis of existing randomized data regarding treatment of atrial fibrillation in heart failure settle the case for catheter ablation?
     Eur Heart J. 2019 Oct 22. pii: 5602553. doi: 10.1093.
     PubMed    
     
     
     
178. REDDY YNV, Obokata M, Wiley B, Koepp KE, et al
     The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction.
     Eur Heart J. 2019 Oct 14. pii: 5586988. doi: 10.1093.
     PubMed     Abstract available
     
     
     
179. RICHTER S, Di Biase L, Hindricks G
     Atrial fibrillation ablation in heart failure: it's not all about Starling my darling.
     Eur Heart J. 2019 Oct 3. pii: 5580540. doi: 10.1093.
     PubMed    
     
     
     September 2019
180. FELKER GM
     Must I keep taking all these medicines? Optimizing diuretics in chronic heart failure.
     Eur Heart J. 2019 Sep 27. pii: 5575243. doi: 10.1093.
     PubMed    
     
     
     
181. CHATHA SR, Westwood M, Moon JC, Captur G, et al
     New-onset heart failure: free-breathing motion-corrected late gadolinium enhancement rescues the endomyocardial fibrosis diagnosis.
     Eur Heart J. 2019 Sep 27. pii: 5575240. doi: 10.1093.
     PubMed    
     
     
     
182. VAN DER WAL HH, Grote Beverborg N, Dickstein K, Anker SD, et al
     Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use.
     Eur Heart J. 2019 Sep 26. pii: 5574384. doi: 10.1093.
     PubMed     Abstract available
     
     
     
183. WIJTVLIET EPJP, Tieleman RG, van Gelder IC, Pluymaekers NAHA, et al
     Nurse-led vs. usual-care for atrial fibrillation.
     Eur Heart J. 2019 Sep 23. pii: 5572602. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2019
184. MCINTYRE WF, Connolly SJ, Wang J, Masiero S, et al
     Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials.
     Eur Heart J. 2019 Aug 4. pii: 5543556. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2019
185. GENTILLE LORENTE DI
     Coconut atrium: a rare entity to cause pulmonary hypertension.
     Eur Heart J. 2019 Jun 4. pii: 5510776. doi: 10.1093.
     PubMed    
     
     
     January 2019
186. WOJAKOWSKI W, Baumgartner H
     The year in cardiology 2018: valvular heart disease.
     Eur Heart J. 2019 Jan 2. pii: 5265301. doi: 10.1093.
     PubMed    
     
     
     
187. CHAO TF, Lip GYH, Lin YJ, Chang SL, et al
     Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.
     Eur Heart J. 2019 Jan 2. pii: 5272355. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2018
188. PETROVIC J, Boricic I, Petrovic M, Ivanovic B, et al
     Endomyocardial fibrosis and unileaflet mitral valve: a fatal postpartum outcome.
     Eur Heart J. 2018 Oct 17. pii: 5137115. doi: 10.1093.
     PubMed    
     
     
     September 2018
189. SZUMMER K, Wallentin L, Lindhagen L, Alfredsson J, et al
     Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014.
     Eur Heart J. 2018 Sep 19. pii: 5103432. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2018
190. POLOVINA M, Hindricks G, Maggioni A, Piepoli M, et al
     Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation.
     Eur Heart J. 2018 Aug 7. pii: 5067645. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2018
191. TOPILSKY Y, Inojosa JM, Benfari G, Vaturi O, et al
     Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction.
     Eur Heart J. 2018 Jul 27. pii: 5060565. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2018
192. YAMAMOTO M, Seo Y, Ishizu T, Aonuma K, et al
     Reversible aortic valve stenosis with Loffler endocarditis.
     Eur Heart J. 2018 Feb 26. pii: 4911114. doi: 10.1093.
     PubMed    
     
     
     
193. RIENSTRA M, Hobbelt AH, Alings M, Tijssen JGP, et al
     Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.
     Eur Heart J. 2018 Feb 1. pii: 4786620. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2018
194. MEHLUM MH, Liestol K, Kjeldsen SE, Julius S, et al
     Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
     Eur Heart J. 2018 Jan 20. pii: 4815726. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2017
195. BERMEJO J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, et al
     Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
     Eur Heart J. 2017 Dec 21. pii: 4769387. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: